The Global Calciphylaxis Treatment Market, by Treatment (Drug Therapy, and Hyperbaric Oxygen Therapy), by End User (Hospital and Clinics, Homecare, and Ambulatory Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,097.7 million in 2017 and is projected to exhibit a CAGR of 9.6% over the forecast period (2018 - 2026).
Calciphylaxis is a rare condition characterized by calcification or the aggregation of calcium in a patient’s blood vessels and the development of thrombosis. This can lead to the death of cells in a patient’s skin and fatty tissues, thereby causing death. Diagnosis of calciphylaxis is symptoms-based and various tests such as skin biopsy, blood tests, and imaging studies confirm the condition. There is no specific treatment available for calciphylaxis. Healthcare professionals often focus on balancing the minerals in the body such as calcium and phosphate that may aid in treatment of the disease. This can be achieved by changing dialysis regimes, medications, or considering surgery for parathyroid glands. Major surgical treatments such as parathyroidectomy are mostly recommended for patients with known primary hyperparathyroidism. However, surgical debridement to remove necrotic tissue and healing of healthy tissue is more widely used, however, its efficacy is debated. Doctors also focus on pain control, good nutrition, and excellent ulcer care in case the skin has broken down. Wound management therapies for calciphylaxis include, nonsurgical wound cleansing and Hyperbaric Oxygen Therapy (HBOT). HBOT can be considered as a second line of treatment incase wounds do not improve. Researchers and key players in the market are focused on finding efficient treatment for calciphylaxis. According to the Journal of the American Society of Nephrology 2017 study, Vitamin K deficiency can have a role in development of calciphylaxis. Moreover, according a study published in 2017 by BioMed Central Nephology Journal, four week supplementation of Vitamin K2 can significantly improve vascular calcification.
Browse 24 Market Data Tables and 21 Figures spread through 165 Pages and in-depth TOC on "Calciphylaxis Treatment Market, by Treatment (Drug Therapy, and Hyperbaric Oxygen Therapy), by End User (Hospital and Clinics, Homecare, and Ambulatory Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to calciphylaxis treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/calciphylaxis-treatment-market-2251
Key Takeaways of the Global Calciphylaxis Treatment Market:
- The global calciphylaxis treatment market is expected to witness a CAGR of 9.6% during the forecast period, owing to increasing cases of calciphylaxis associated with dialysis. According to the Nephrology Dialysis Transplantation Journal 2017 study, the German Calciphylaxis Registry recorded calciphylaxis reporting rate of approximately 30 new cases per year among the dialysis patients between 2006 to 2015
- Among region, North America calciphylaxis treatment market is expected to generate maximum revenue during the forecast period, owing to increasing demand for kidney transplantation procedures and rising number of dialysis patients. According to the National Kidney Foundation, in 2016, around 3,000 patients every month underwent kidney transplant in the U.S.
- Major players operating in the global calciphylaxis treatment market include, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.
